BiotechTube
Ibex Medical Analytics

Ibex Medical Analytics

Tel Aviv, United States· Est.
ibex-ai.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $104M

Overview

Ibex Medical Analytics is a pioneering leader in AI-powered digital pathology for cancer diagnostics. Its Galen platform, trained on millions of slides and expert pathologist input, provides real-time decision support to detect and grade cancers in prostate, breast, and other tissues. The company has achieved significant commercial traction with live clinical deployments globally, is backed by a strong Series C funding round, and is positioned at the convergence of digital pathology adoption and AI-driven precision diagnostics.

Oncology

Technology Platform

Galen AI platform: A multi-algorithm, AI-powered decision support system for digital pathology. Trained on >10 million slides to detect and grade cancer and numerous other diagnostic features in tissue biopsies.

Funding History

3
Total raised:$104M
Series C$55M
Series B$38M
Series A$11M

Opportunities

The rapid adoption of digital pathology scanners creates a growing installed base for its AI software.
The global shortage of pathologists and need for diagnostic standardization drives demand for efficiency-enhancing tools.
Expansion into new cancer types and predictive biomarker analysis from H&E images represents significant future growth avenues.

Risk Factors

Regulatory approval processes for software as a medical device are complex and vary by region.
Market growth is contingent on the capital-intensive adoption of digital pathology scanners by healthcare institutions.
Algorithm performance must generalize across diverse patient populations and laboratory practices to maintain clinical trust.

Competitive Landscape

Ibex competes with other AI pathology firms like Paige, PathAI, and Proscia, as well as in-house efforts from large diagnostic companies and scanner manufacturers (e.g., Roche, Philips). Its key competitive advantages are its early commercial deployments, a large and diverse training dataset, and a focus on multi-feature detection within live clinical workflows.

More companies in United States →